209116

NFkB-p50, Recombinant, Human, Active, GST-Tag (Nuclear Factor NF-kappa-B p105 Subunit, Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells)

Size

£810.00

SKU:: 209116
Molecular Weight:: 75
Purity:: Highly Purified (~95%)
Storage Conditions:: -70°C
Supplier:: United States Biological
Format:: Supplied as a liquid in PBS, pH 7.4, 5mM DTT, 20% glycerol.
Extra Details:: NF-_x0001_B (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex that controls the transcription of DNA. NF-_x0001_B is found in almost all animal cell types and is involved in cellular responses to stimuli such as stress, cytokines, free radicals, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens. NF-_x0001_B plays a key role in regulating the immune response to infection (kappa light chains are critical components of immunoglobulins). Incorrect regulation of NF-_x0001_B has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development. NF- _x0001_B has also been implicated in processes of synaptic plasticity and memory. NF-_x0001_B was first discovered via its interaction with an 11-base pair sequence in the immunoglobulin light-chain enhancer in B cells. All proteins of the NF-_x0001_B family share a Rel homology domain in their N-terminus. A subfamily of NF-_x0001_B proteins, including RelA, RelB, and c-Rel, have a transactivation domain in their C-termini. In contrast, the NF-_x0001_B1 and NF-_x0001_B2 proteins are synthesized as large precursors, p105, and p100, which undergo processing to generate the mature NF-_x0001_B subunits, p50 and p52, respectively. The processing of p105 and p100 is mediated by the ubiquitin/proteasome pathway and involves selective degradation of their C-terminal region containing ankyrin repeats. Whereas the generation of p52 from p100 is a tightly-regulated process, p50 is produced from constitutive processing of p105. NF-_x0001_B is a major transcription factor that regulates genes responsible for both the innate and adaptive immune response. Upon activation of either the T- or B-cell receptor, NF-_x0001_B becomes activated through distinct signaling components. Upon ligation of the T-cell receptor, protein kinase Lck is recruited and phosphorylates the ITAMs of the CD3 cytoplasmic tail. ZAP70 is then recruited to the phosphorylated ITAMs and helps recruit LAT and PLC-gamma, which causes activation of PKC. Through a cascade of phosphorylation events, the kinase complex is activated and NF-_x0001_B is able to enter the nucleus to upregulate genes involved in T-cell development, maturation, and proliferation. Aberrant activation of NF-_x0001_B is frequently observed in many cancers. Moreover, suppression of NF-_x0001_B limits the proliferation of cancer cells. In addition, NF-_x0001_B is a key player in the inflammatory response. Hence methods of inhibiting NF-_x0001_B signaling has potential therapeutic application in cancer and inflammatory diseases. A new drug called denosumab acts to raise bone mineral density and reduce fracture rates in many patient sub- groups by inhibiting RANKL. Source: Recombinant protein corresponding to full-length NFkB-p50, fused to GST-tag, expressed in E. coli. Molecular Weight: ~75kD Specific Activity: ~40units/mg Applications: Suitable for use as Positive Control for ELISA and Western Blot. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: Aliquot to avoid repeated freezing and thawing and store at -70°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Shipping Conditions:: Dry Ice